TRVN - What's Going On With Neurological Disease Focused Trevena On Thursday? | Benzinga
Shares of Trevena Inc (NASDAQ:TRVN) are trading lower on Thursday, with a session volume of 23.65 million, as per data from Benzinga Pro.
The company released preclinical data from two separate research collaborations.
The first studies examined the cellular mechanism of analgesic effects of TRV045, a novel S1P1 receptor modulator, in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN).
The second set of studies was from a separate, ongoing collaboration with the NIH-supported Epilepsy Therapy Screening Program (ETSP), which studied the use of TRV045 in three different preclinical models, examining its potential effects on acute seizure protection and its potential ability to modify seizure development, or epileptogenesis.
In this study, TRV045 did not cause S1P1R functional desensitization or S1PR1 protein reduction despite repeated ...